References
- Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45–59.
- Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJ, Westermark P. Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis. Amyloid 2010;17:101–104.
- Biewend ML, Menke DM, Calamia KT. The spectrum of localized amyloidosis: a case series of 20 patients and review of the literature. Amyloid 2006;13:135–142.
- Utz JP, Swensen SJ, Gertz MA. Pulmonary amyloidosis. The Mayo Clinic experience from 1980 to 1993. Ann Intern Med 1996;124:407–413.
- Eby C. Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias. Br J Haematol 2009;145:151–163.
- Mumford AD, O’Donnell J, Gillmore JD, Manning RA, Hawkins PN, Laffan M. Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis. Br J Haematol 2000;110:454–460.
- Sucker C, Hetzel GR, Grabensee B, Stockschlaeder M, Scharf RE. Amyloidosis and bleeding: pathophysiology, diagnosis, and therapy. Am J Kidney Dis 2006;47:947–955.
- Kos CA, Ward JE, Malek K, Sanchorawala V, Wright DG, O’Hara C, Connors L, et al. Association of acquired von Willebrand syndrome with AL amyloidosis. Am J Hematol 2007;82:363–367.
- Maas C, Govers-Riemslag JW, Bouma B, Schiks B, Hazenberg BP, Lokhorst HM, Hammarström P, et al. Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation. J Clin Invest 2008;118:3208–3218.
- Takahashi H, Koike T, Yoshida N, Kitahara O, Hanano M, Shibata A, Aoki N. Excessive fibrinolysis in suspected amyloidosis: demonstration of plasmin-α 2-plasmin inhibitor complex and von Willebrand factor fragment in plasma. Am J Hematol 1986;23:153–166.
- Gamba G, Montani N, Anesi E, Palladini G, Capezzera M, Soldavini E, Merlini G. Clotting alterations in primary systemic amyloidosis. Haematologica 2000;85:289–292.
- Bouma B, Maas C, Hazenberg BP, Lokhorst HM, Gebbink MF. Increased plasmin-α2-antiplasmin levels indicate activation of the fibrinolytic system in systemic amyloidoses. J Thromb Haemost 2007;5:1139–1142.
- Uchiba M, Imamura T, Hata H, Tatetsu H, Yonemura Y, Ueda M, Wada Y, et al. Excessive fibrinolysis in AL-amyloidosis is induced by urokinae-type plasminogen activator from bone marrow plasma cells. Amyloid 2009;16:89–93.
- Holvoet P, de Boer A, Verstreken M, Collen D. An enzyme-linked immunosorbent assay (ELISA) for the measurement of plasmin-α 2-antiplasmin complex in human plasma–application to the detection of in vivo activation of the fibrinolytic system. Thromb Haemost 1986;56:124–127.
- Elidrissy AT, Abdurrahman MB, Bahakim HM, Jones MD, Gader AM. Haemostatic measurements in childhood nephrotic syndrome. Eur J Pediatr 1991;150:374–378.